Understanding how kappa opioid receptors work to relieve itching
Deciphering the complex pharmacology of kappa opioid receptor: Towards the understanding of a third signaling pathway and its essential role in antipruritic effect
This study is looking into how a specific receptor in the body can help reduce itching, with the hope of finding new ways to treat conditions that cause severe itchiness, so people can feel more comfortable.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11054696 on NIH RePORTER |
What this research studies
This research investigates the complex signaling pathways of kappa opioid receptors (KOR) that play a role in reducing itchiness. By exploring how KOR interacts with various proteins and pathways in the body, the study aims to uncover new mechanisms that could lead to better treatments for conditions that cause severe itching. The research involves both laboratory experiments and analysis of cellular responses to KOR activation, focusing on how these interactions can influence itch relief. Patients may benefit from insights gained into new therapeutic targets for itch management.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing chronic itch due to various dermatological or systemic conditions.
Not a fit: Patients with acute itch that is easily managed or those without any itch-related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for patients suffering from chronic itching.
How similar studies have performed: While the specific signaling pathways being investigated are novel, previous research has shown that targeting GPCRs can lead to significant advancements in treatment options.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Inan, Saadet — Temple Univ of the Commonwealth
- Study coordinator: Inan, Saadet
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.